Loading
CAR-T Cell Therapy Research / Virus-based Gene Therapy Research / Cancer Research and Treatments · Journal article
Asian Journal of Research in Biochemistry · August 10, 2026
A consensus or society position rather than new primary data.
This narrative review identifies six shared molecular modules through which microbial therapies (bacteria, viruses, microbiome manipulation) engage anti-tumour immunity, and demonstrates that two licensed agents (BCG and talimogene laherparepvec) have achieved clinical utility. However, maturity of evidence is highly heterogeneous: most engineered bacteria remain supported only by preclinical models, oncolytic viruses show phase I/II signals that have not translated reliably to survival benefit in randomised trials, and microbiome biomarkers are reproducible at ecological but not individual-taxa levels.
Narrative review with transparent systematic literature search. Published preclinical (in vitro, murine model) and clinical (early-phase, randomised trial) studies of microbial interventions in cancer therapy.. Intervention: Microbial interventions: Bacillus Calmette–Guérin, talimogene laherparepvec, engineered bacterial therapeutics, oncolytic viruses, and faecal microbiota transplantation.. Compared with: Conventional anticancer medicines; standard of care (implicit in clinical trial comparisons discussed)..
Bacillus Calmette–Guérin and talimogene laherparepvec have achieved clinical utility, demonstrating proof of principle for live microbial products Most engineered bacteria remain supported mainly by murine models and early-phase studies Oncolytic viruses produced durable responses in selected settings but phase I or II signals have not always translated into improved survival in randomised trials
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize that only BCG and talimogene laherparepvec have proven clinical utility among microbial therapies. Most engineered bacterial and oncolytic virus candidates remain experimental; microbiome biomarkers require validation before clinical use. Future development depends on mechanism-linked biomarkers and standardised pharmacodynamic measurements rather than potency alone.
A narrative review synthesizing molecular mechanisms and translational evidence across multiple microbial therapy platforms, identifying shared pathways and maturity gaps rather than reporting a single trial outcome.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize that only BCG and talimogene laherparepvec have proven clinical utility among microbial therapies. Most engineered bacterial and oncolytic virus candidates remain experimental; microbiome biomarkers require validation before clinical use. Future development depends on mechanism-linked biomarkers and standardised pharmacodynamic measurements rather than potency alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Microbial interventions are being developed as anticancer agents, local drug factories, replicating immunotherapies and modifiers of treatment response. Their appeal arises from properties that conventional medicines do not readily reproduce: active replication, environmental sensing, penetration of poorly perfused tissue, programmable payload production and the capacity to engage innate and adaptive immunity. This critical narrative review evaluates tumour-targeting bacteria, engineered bacterial therapeutics, oncolytic viruses and manipulation of the host microbiome from a molecular-biology perspective. Literature published from 1 January 1990 to 29 May 2026 was selected through a transparent search of PubMed/MEDLINE, reference chaining and bibliographic verification of article identity and Digital Object Identifiers. The evidence indicates that microbial therapies operate through partially shared molecular modules: selective localisation or replication, pattern-recognition receptor signalling, immunogenic cell injury, antigen release and cross-presentation, metabolic reprogramming, and spatially restricted expression of therapeutic cargo. Yet the maturity of evidence differs sharply across platforms. Bacillus Calmette–Guérin and talimogene laherparepvec demonstrate that live microbial products can achieve clinical utility, whereas most engineered bacteria remain supported mainly by murine models and early-phase studies. Oncolytic viruses have produced durable responses in selected settings, but apparently strong phase I or II signals have not always translated into improved survival in randomised trials. Gut-microbiome associations with immune-checkpoint inhibitor outcomes are reproducible at a broad ecological level but inconsistent at the level of individual taxa; early faecal microbiota transplantation studies provide proof of principle rather than definitive efficacy. Across platforms, the central translational problem is not simply potency but control: biodistribution, genetic stability, inflammatory dose, immune clearance, manufacturing consistency and reversibility must be treated as molecular design variables. Progress will depend on mechanism-linked biomarkers, standardised pharmacodynamic measurements, rational combination trials and containment architectures that are validated under clinically realistic conditions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.